We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+42.82%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$417M
AUM Growth
+$95.9M
Cap. Flow
-$11.1M
Cap. Flow %
-2.67%
Top 10 Hldgs %
49.63%
Holding
82
New
7
Increased
14
Reduced
24
Closed
6

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$4.86M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$4.37M
3
BHVN icon
Biohaven
BHVN
+$4.16M
4
SLRN
ACELYRIN
SLRN
+$3.11M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.58M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$8.98M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.02M
3
NRIX icon
Nurix Therapeutics
NRIX
+$4.38M
4
CYTK icon
Cytokinetics
CYTK
+$2.88M
5
AUTL
Autolus Therapeutics
AUTL
+$2.81M

Sector Composition

Rank Sector Weight
1 Healthcare 85.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.25M 1.26%
89,387
-3,500
-4% -$197K
EWTX icon
27
Edgewise Therapeutics
EWTX
$4.78B
$4.92M 1.18%
449,384
-70,000
-13% -$491K
ALEC icon
28
Alector
ALEC
$171M
$4.87M 1.17%
609,905
-19,033
-3% -$113K
VKTX icon
29
Viking Therapeutics
VKTX
$3.92B
$4.62M 1.11%
248,217
-71,438
-22% -$934K
ATRC icon
30
AtriCure
ATRC
$2.03B
$4.48M 1.07%
125,529
– –
RCUS icon
31
Arcus Biosciences
RCUS
$3.56B
$4.44M 1.07%
232,717
+10,000
+4% +$160K
IPSC icon
32
Century Therapeutics
IPSC
$357M
$4.34M 1.04%
1,307,407
– –
BCRX icon
33
BioCryst Pharmaceuticals
BCRX
$2.36B
$4.25M 1.02%
709,500
+57,500
+9% +$333K
ARAY icon
34
Accuray
ARAY
$34.2M
$3.46M 0.83%
1,222,358
– –
ATXS
35
DELISTED
Astria Therapeutics
ATXS
$3.45M 0.83%
449,008
+153,515
+52% +$849K
KROS icon
36
Keros Therapeutics
KROS
$200M
$2.96M 0.71%
74,361
+8,400
+13% +$263K
SLRN
37
DELISTED
ACELYRIN
SLRN
$2.77M 0.66%
371,200
+363,900
+4,985% +$3.11M
PRCT icon
38
Procept Biorobotics
PRCT
$1.09B
$2.65M 0.64%
63,300
-4,000
-6% -$136K
MDWD icon
39
MediWound
MDWD
$187M
$2.62M 0.63%
257,653
– –
BCYC
40
Bicycle Therapeutics
BCYC
$278M
$2.21M 0.53%
122,200
– –
BWAY
41
Brainsway
BWAY
$647M
$2M 0.48%
616,942
-247,420
-29% -$599K
PRQR icon
42
ProQR Therapeutics
PRQR
$281M
$1.86M 0.45%
940,582
– –
AMLX icon
43
Amylyx Pharmaceuticals
AMLX
$2.59B
$1.8M 0.43%
122,547
– –
MREO
44
Mereo BioPharma
MREO
$47.7M
$1.8M 0.43%
778,813
-183,700
-19% -$351K
IMVT icon
45
Immunovant
IMVT
$8.03B
$1.72M 0.41%
40,742
+18,242
+81% +$671K
SPRY icon
46
ARS Pharmaceuticals
SPRY
$544M
$1.71M 0.41%
+311,169
New +$1.36M
CMPS
47
Compass Pathways
CMPS
$1.82B
$1.69M 0.4%
193,000
– –
SYRS
48
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.67M 0.4%
214,885
-50,993
-19% -$175K
SPRB
49
Spruce Biosciences
SPRB
$129M
$1.61M 0.39%
7,313
-289
-4% -$33.4K
LRMR icon
50
Larimar Therapeutics
LRMR
$435M
$1.47M 0.35%
323,873
-3,500
-1% -$11.8K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, DAFNA Capital Management held 82 positions worth $417M, up 30% from $321M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management's Q4 2023 filing shows 7 new, 14 increased, 24 reduced and 6 closed positions. Its largest new stake was Sage Therapeutics: 245,000 shares worth $5.31M. The largest sale was Blueprint Medicines, an estimated $8.98M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier.

  • DAFNA Capital Management's largest Q4 2023 buy was Sage Therapeutics: 245,000 shares worth $5.31M.
  • DAFNA Capital Management added most to Syndax Pharmaceuticals in Q4 2023, an estimated $4.37M increase.
  • DAFNA Capital Management's biggest Q4 2023 reduction was Blueprint Medicines, cutting an estimated $8.98M.
  • DAFNA Capital Management fully exited Nurix Therapeutics in Q4 2023, selling an estimated $4.38M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $417M portfolio in Q4 2023.
  • DAFNA Capital Management opened 7 new positions and closed 6 in Q4 2023.
  • DAFNA Capital Management's portfolio value rose 30% quarter-over-quarter to $417M.

Based on DAFNA Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.